Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (ARQT) has granted a total of 44,000 restricted stock units (RSUs) to six newly hired employees. The grants were approved by the company's Compensation Committee and issued under the 2022 Inducement Plan on December 2, 2024. The RSUs will vest over a four-year period, with 25% vesting annually, contingent on continuous employment. This action complies with Nasdaq Listing Rule 5635(c)(4), which governs inducement grants for new employees.
Arcutis Biotherapeutics (ARQT) ha concesso un totale di 44.000 unità di azioni riservate (RSU) a sei nuovi dipendenti. Le concessioni sono state approvate dal Comitato Compensi dell'azienda e rilasciate nell'ambito del Piano di Induzione 2022 il 2 dicembre 2024. Le RSU si matureranno nel corso di un periodo di quattro anni, con il 25% che matura annualmente, a condizione di un impiego continuativo. Questa azione è conforme alla Regola di Quotazione Nasdaq 5635(c)(4), che regola le concessioni di indennità per nuovi dipendenti.
Arcutis Biotherapeutics (ARQT) ha otorgado un total de 44,000 unidades de acciones restringidas (RSUs) a seis empleados recién contratados. Las concesiones fueron aprobadas por el Comité de Compensación de la empresa y emitidas bajo el Plan de Inducción 2022 el 2 de diciembre de 2024. Las RSUs se consolidarán durante un período de cuatro años, con un 25% consolidándose anualmente, sujeto a empleo continuo. Esta acción cumple con la Regla de Cotización de Nasdaq 5635(c)(4), que regula las concesiones de incentivo para nuevos empleados.
Arcutis Biotherapeutics (ARQT)는 여섯 명의 새로 고용된 직원에게 총 44,000개의 제한 주식 단위(RSU)를 부여했습니다. 이러한 부여는 회사의 보상 위원회에 의해 승인되었으며, 2022 유도 계획에 따라 2024년 12월 2일에 이루어졌습니다. RSU는 4년 동안 분할 지급되며, 매년 25%가 지급되며 지속적인 고용을 조건으로 합니다. 이 조치는 신규 직원에 대한 유도 보상의 규정을 정하는 Nasdaq 상장 규칙 5635(c)(4)에 부합합니다.
Arcutis Biotherapeutics (ARQT) a accordé un total de 44 000 unités d'actions restreintes (RSU) à six nouveaux employés. Les attributions ont été approuvées par le Comité de rémunération de l'entreprise et émises dans le cadre du Plan d'incitation 2022 le 2 décembre 2024. Les RSU s'acquitteront sur une période de quatre ans, avec 25% qui s'acquittent chaque année, sous réserve d'un emploi continu. Cette action est conforme à la règle de cotation Nasdaq 5635(c)(4), qui régit les attributions d'incitation pour les nouveaux employés.
Arcutis Biotherapeutics (ARQT) hat insgesamt 44.000 eingeschränkte Aktieneinheiten (RSUs) an sechs neu eingestellte Mitarbeiter vergeben. Die Zuwendungen wurden vom Vergütungsausschuss des Unternehmens genehmigt und am 2. Dezember 2024 im Rahmen des Induktionsplans 2022 ausgegeben. Die RSUs werden über einen Zeitraum von vier Jahren angesammelt, wobei jährlich 25 % anfallen, vorausgesetzt, das Beschäftigungsverhältnis bleibt bestehen. Diese Maßnahme entspricht der Nasdaq-Listing-Regel 5635(c)(4), die Anreizgewährungen für neue Mitarbeiter regelt.
- None.
- None.
WESTLAKE VILLAGE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 44,000 restricted stock units of Arcutis’ common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of December 2, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Corporate Controller
ir@arcutis.com
FAQ
How many restricted stock units did Arcutis Biotherapeutics (ARQT) grant on December 2, 2024?
What is the vesting schedule for ARQT's December 2024 restricted stock unit grants?
Under which plan were ARQT's December 2024 inducement grants issued?
